Baxter International, Inc.
One Baxter Parkway
About Baxter International, Inc.
Baxter touches millions of lives every day. Our products and services are essential building blocks of healthcare.
You’ll find Baxter’s products and therapies on nearly every floor, in every department, in almost every hospital worldwide. You’ll find us in clinics and in the home. Patients and providers rely on Baxter for lifesaving renal and medical products, including intravenous (IV) solutions, systems and administrative sets, IV infusion parenteral nutrition, perioperative care, pharmacy devices and software, acute renal care, and home and in-center dialysis.
Our mission to save and sustain lives inspires our work and our commitment to expanding access to care, providing cost-effective healthcare solutions, delivering quality products and advancing innovations for the world.
Our commitment to our mission means we are there when patients and healthcare professionals need us, during the critical moments that matter most.
CEO: José (Joe) E. Almeida
CMO: James R. Gavin III
CTO: Uma Chowdhry
CFO: Peter Hellman
FOLLOW BAXTER INTERNATIONAL:
Tweets by Baxer International
911 articles with Baxter International, Inc.
Second-quarter revenue of $2.7 billion decreased 4% on a reported basis, 1% on a constant currency basis and 2% on an operational basis1
Companies forge exclusive partnership to advance digital health solutions that educate and empower patients with kidney failure The companies’ first mobile app, CKD&Me , launched in the United States; now preparing for global expansion Collaboration expected to also bring new patient mobile capabilities to Baxter’s Sharesource telehealth platform to support patient engagement and therapy management DEERFIELD, Ill. &
Baxter and VIPUN Medical Announce Collaboration to Commercialize Innovative Gastric Monitoring System to Help Enhance Clinical Nutrition
Innovative system measures stomach motility to help clinicians identify enteral feeding intolerance Technology designed to help address malnutrition in the ICU and support clinical decision-making Baxter gains exclusive distribution rights to bring system to clinicians worldwide
Baxter International Inc., a leading global medical products company, announced it has been named a top-scoring company on the 2020 Disability Equality Index® by Disability:IN, the leading nonprofit resource for business disability inclusion worldwide.
Baxter International Inc., a leading global medical products company, announced that its Board of Directors has declared a quarterly cash dividend of $0.245 per share of common stock.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its second-quarter 2020 financial results on Thursday, July 30, 2020, at 7:30 a.m. Central Time.
Designed to enhance bone growth and help achieve fusion in surgeries involving the skeletal system Recent study shows posterolateral fusion success associated with improved patient outcomes, including reduced pain from baseline New configurations give surgeons versatile options that are easy to mold DEERFIELD, Ill.--( BUSINESS WIRE )-- Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today
Baxter Publishes 2019 Corporate Responsibility Report, Highlighting Efforts to Make a Meaningful Difference as a Leading Global Corporate Citizen
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today released its 2019 Corporate Responsibility Report . The report, published annually, details progress towards realizing the company’s Corporate Responsibility priorities and goal
Baxter Receives CE Marking and Australian Regulatory Approval for Evo IQ Syringe Infusion System, Building on Smart Pump Platform
New addition to Baxter’s Evo IQ Infusion Platform complements on-market large volumetric pump, offering opportunity to further help personalize treatment Incorporates web-based Dose IQ Safety Software and wireless IQ Enterprise Connectivity Suite to maximize drug library management and advance patient safety Designed to optimize efficiency for clinicians, with the flexibility to help meet future needs DEERFIELD, Ill.--( BUSINE
Baxter Announces Results of Clinical Trial on Benefits of Dynamic Fluid Management in Septic Shock Patients
Results published in CHEST Journal demonstrate benefits of using dynamic measures to guide fluid therapy decisions
Baxter International Inc. announced an increase in the company’s quarterly cash dividend to a rate of $0.245 per share of common stock.
Baxter International Inc., a leading global medical products company, reported results for the first quarter of 2020.
Baxter International Inc., a leading global medical products company, will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 via webcast.
Baxter Obtains U.S. FDA Emergency Use Authorization for Oxiris Blood Purification Filter for COVID-19 Treatment
Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received emergency use authorization (EUA) from the U.S. FDA for the company’s Oxiris filter set to treat patients who have confirmed COVID-19 and have been admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure in need of blood purification therapy to reduce pro-inflammatory cytokine levels, including use in continuous renal replacement therapy (CRRT).
Baxter International Inc., a leading global medical products company, will host a conference call to discuss its first-quarter 2020 financial results on Thursday, April 30, 2020, at 7:30 a.m. Central Time..
Maximizing production of critical medical products to support increased patient care levels Protecting employee health and safety through enhanced infection control procedures Hiring up to 2,000 new employees globally -- 800 to join Baxter’s U.S. operations
Baxter International Inc. announced that, due to the public health and safety concerns related to the novel coronavirus pandemic and recommendations and orders from Federal and Illinois authorities, its Annual Meeting of Stockholders will now be held by means of a virtual format only.
Fourth-quarter GAAP earnings per share (EPS) were a loss of $0.05; adjusted EPS 1 totaled $0.97
Baxter International Inc., a leading global medical products company, will host a conference call to discuss its fourth-quarter 2019 financial results on Tuesday, March 17, 2020, at 7:30 a.m. Central Time.
Baxter Launches Peri-Strips Dry With Secure Grip Technology for Reliable Staple Line Reinforcement in Surgical Procedures
Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, announced 510(k) clearance from the U.S. Food and Drug Administration for a new generation of its Peri-Strips Dry with Veritas Collagen Matrix (PSDV) product, known as PSDV with Secure Grip